MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Начало・Списък с акции・MacroGenics Inc

MacroGenics Inc

Затворен

СекторЗдравеопазване

1.06 -7.83

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.03

Максимум

1.15

Ключови измерители
By Trading Economics
Приходи	-72M -15M
Продажби	-93M 18M
P/E Средно за сектора	38.83 63.778
EPS	-0.818
Марж на печалбата	-86.977
Служители	341
EBITDA	-71M -12M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+421.74% upside

Дивиденти
By Dow Jones
Следващи печалби	8.05.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-107M 80M
Предишно отваряне	8.89
Предишно затваряне	1.06

Настроения в новините

By Acuity

87%

13%

371 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

N/A / 1.22 Подкрепа & съпротива

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.04.2025 г., 22:38 ч. UTC

Горещи акции

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

4.04.2025 г., 21:53 ч. UTC

Пазарно говорене

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4.04.2025 г., 21:44 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

4.04.2025 г., 21:00 ч. UTC

Топ новини

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

4.04.2025 г., 20:52 ч. UTC

Пазарно говорене

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

4.04.2025 г., 20:52 ч. UTC

Топ новини

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

4.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

4.04.2025 г., 20:48 ч. UTC

Топ новини

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

4.04.2025 г., 20:45 ч. UTC

Топ новини

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

4.04.2025 г., 20:32 ч. UTC

Топ новини

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

4.04.2025 г., 20:21 ч. UTC

Топ новини

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

4.04.2025 г., 20:00 ч. UTC

Топ новини

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

4.04.2025 г., 19:51 ч. UTC

Пазарно говорене

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

4.04.2025 г., 19:37 ч. UTC

Топ новини

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

4.04.2025 г., 19:32 ч. UTC

Пазарно говорене

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

4.04.2025 г., 19:28 ч. UTC

Топ новини

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

4.04.2025 г., 19:15 ч. UTC

Пазарно говорене

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

4.04.2025 г., 19:12 ч. UTC

Топ новини

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

4.04.2025 г., 19:11 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

4.04.2025 г., 19:09 ч. UTC

Пазарно говорене

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

4.04.2025 г., 19:09 ч. UTC

Топ новини

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

4.04.2025 г., 19:00 ч. UTC

Пазарно говорене

Fed Has Limited Options to Counter Tariffs -- Market Talk

4.04.2025 г., 18:53 ч. UTC

Пазарно говорене

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

4.04.2025 г., 18:51 ч. UTC

Пазарно говорене

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

4.04.2025 г., 18:44 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

4.04.2025 г., 18:44 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.04.2025 г., 18:44 ч. UTC

Пазарно говорене

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

4.04.2025 г., 18:43 ч. UTC

Придобивния, сливания и поглъщания

Trump Extends Deadline for TikTok Ban Another 75 Days. ByteDance Says 'An Agreement Has Not Been Executed.' -- Barrons.com

4.04.2025 г., 18:43 ч. UTC

Придобивния, сливания и поглъщания

Trump Extends TikTok Ban Deadline A Second Time As Deal Chatter Swirls -- IBD

4.04.2025 г., 18:39 ч. UTC

Пазарно говорене

Protectionism is Back, And Recession Could Follow, Morgan Stanley Says -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

421.74% нагоре

12-месечна прогноза

Среден 6 USD 421.74%

Висок 8 USD

Нисък 2 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на MacroGenics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 1.22Подкрепа & съпротива

All events are bearish.

Настроение

By Acuity

371 / 386 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.